Established in 2004, Changzhou Rui Ming Pharmaceutical Co., Ltd is located at No. 1558, Longjiang North Road, Chunjiang Town, Xinbei District, Changzhou City, Jiangsu Province.

Our company enjoys convenient transportation and superior environment for we are adjacent to the Yangtze River and Shanghai-Nanjing Expressway.

Covering an area of ​​25,000 square meters, our company now has 9 main buildings: three chemical synthesis plants, one fine baking plant (in accordance with GMP requirements), a liquid raw material warehouse, a solid raw material warehouse (separated into raw auxiliary material warehouse, intermediate warehouse and finished product warehouse), power room, machine maintenance room, office building and living building.

Now, our company implements GMP requirements for all activities involved in the production and quality management process.

We produce three APIs by now, which were certificated to Chinese GMP inspections in July 2009, July 2011 and July 2015; propafenone hydrochloride, felodipine and amlodipine besylate. Especially, amlodipine besylate obtained the CEP certificate of EOQM in August 2011, and the updated CEP certificate in August 2016. We passed the EU-conducted on-site audit in May 2017, and the PMDA (Japan) on-site audit in December 2017，In September 2018, tamsulosin hydrochloride successfully passed the on-site inspection conducted by the FDA. In August 2019, methoxyphenamine hydrochloride passed the GMP on-site inspection. In December 2022, tamsulosin hydrochloride successfully underwent registration on-site verification and GMP compliance inspection. In June 2023, levamlodipine besylate passed the GMP compliance inspection. In November 2023, amlodipine besylate passed the on-site audit conducted by the European Union's EDQM. In May 2024, amlodipine besylate, felodipine, propafenone hydrochloride, methoxyphenamine hydrochloride, levamlodipine besylate, and tamsulosin hydrochloride all passed the GMP compliance inspection.

"Technology and innovation" is the eternal pursuit of our company. Because we are deeply concerned about the improvement of R&D technology, we not only introduce a group of outstanding talents, but also have established good cooperative relations with China Pharmaceutical University and Colleges and Universities in Shanghai in terms of product technology.

Our company sincerely welcomes customers all around the world to contact with Ruiming; let's work together to seek cooperation opportunities and common development.

Anhui Norcon Pharmaceutical Co., Ltd. was founded on April 17, 2008, formerly known as Chizhou Ruike Pharmaceutical Co., Ltd.

The company covers an area of 55,000 square meters and is located in the Dongzhi Economic Development Zone, Chizhou City, Anhui Province, with convenient transportation.

The drug production license was obtained in September 2022. The production scope of the drug production license includes active pharmaceutical ingredients (APIs) such as fosfomycin trometamol, roxatidine acetate hydrochloride, labetalol hydrochloride, and topiramate

Obtain the fosfomycin trometamol CEP certificate in 2024